X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (1181) 1181
rosuvastatin calcium (899) 899
male (855) 855
humans (824) 824
female (573) 573
animals (489) 489
fluorobenzenes - administration & dosage (482) 482
rosuvastatin (449) 449
fluorobenzenes - therapeutic use (444) 444
middle aged (422) 422
fluorobenzenes - pharmacology (398) 398
pyrimidines - administration & dosage (397) 397
sulfonamides - administration & dosage (397) 397
sulfonamides - therapeutic use (393) 393
pyrimidines - therapeutic use (391) 391
statins (342) 342
hydroxymethylglutaryl-coa reductase inhibitors - therapeutic use (341) 341
hydroxymethylglutaryl-coa reductase inhibitors - administration & dosage (340) 340
pharmacology & pharmacy (329) 329
aged (306) 306
rats (282) 282
cardiac & cardiovascular systems (255) 255
dose-response relationship, drug (247) 247
treatment outcome (246) 246
adult (239) 239
atorvastatin (239) 239
cholesterol (212) 212
sulfonamides - pharmacology (204) 204
pyrimidines - pharmacology (198) 198
cholesterol, ldl - blood (192) 192
fluorobenzenes - adverse effects (177) 177
simvastatin (171) 171
abridged index medicus (170) 170
atorvastatin calcium (165) 165
hydroxymethylglutaryl-coa reductase inhibitors - pharmacology (164) 164
sulfonamides - adverse effects (163) 163
pyrimidines - adverse effects (162) 162
hydroxymethylglutaryl-coa reductase inhibitors - adverse effects (151) 151
pravastatin (147) 147
fluorobenzenes - pharmacokinetics (145) 145
mice (134) 134
hypercholesterolemia - drug therapy (132) 132
rats, sprague-dawley (132) 132
antilipemic agents (131) 131
time factors (128) 128
neurosciences (127) 127
atherosclerosis (123) 123
piperidines - pharmacology (122) 122
cardiovascular (120) 120
drug therapy (118) 118
coronary-heart-disease (115) 115
double-blind method (113) 113
medicine, general & internal (110) 110
heptanoic acids - administration & dosage (108) 108
hypercholesterolemia (108) 108
pyrroles - administration & dosage (108) 108
serotonin antagonists - pharmacology (107) 107
drug therapy, combination (104) 104
c-reactive protein (103) 103
pyrimidines - pharmacokinetics (102) 102
sulfonamides - pharmacokinetics (102) 102
lipids (98) 98
risk (98) 98
risk factors (97) 97
dosage and administration (96) 96
drug interactions (96) 96
peripheral vascular disease (95) 95
statin therapy (93) 93
prevention (92) 92
analysis (88) 88
pharmacokinetics (87) 87
prospective studies (87) 87
heptanoic acids - therapeutic use (85) 85
pyrroles - therapeutic use (85) 85
disease (84) 84
statin (83) 83
density-lipoprotein cholesterol (82) 82
cardiovascular disease (81) 81
hydroxymethylglutaryl-coa reductase inhibitors - pharmacokinetics (79) 79
cardiovascular diseases - prevention & control (78) 78
disease models, animal (78) 78
drug administration schedule (78) 78
rats, wistar (78) 78
research (78) 78
anticholesteremic agents - therapeutic use (73) 73
follow-up studies (73) 73
efficacy (72) 72
cardiology (70) 70
inflammation (70) 70
cholesterol, hdl - blood (67) 67
hyperlipidemias - drug therapy (67) 67
lipids - blood (67) 67
safety (67) 67
care and treatment (66) 66
serotonin (66) 66
anticholesteremic agents - administration & dosage (65) 65
dyslipidemias - drug therapy (65) 65
hypercholesterolemia - blood (65) 65
cholesterol - blood (64) 64
fluorobenzenes - blood (64) 64
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1203) 1203
Russian (11) 11
German (7) 7
Italian (7) 7
French (4) 4
Hungarian (2) 2
Ukrainian (2) 2
Chinese (1) 1
Czech (1) 1
Japanese (1) 1
Spanish (1) 1
Swedish (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


British Journal of Clinical Pharmacology, ISSN 0306-5251, 08/2012, Volume 74, Issue 2, pp. 336 - 345
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT • In healthy subjects, GSK2248761 was shown to be safe and well tolerated with single doses up to 1200 mg once daily... 
NNRTI | HIV‐1 infection | antiretroviral therapy | drug‐drug interaction | HIV-1 infection | Drug-drug interaction | Antiretroviral therapy | PHARMACOKINETICS | TOLERABILITY | PHARMACOLOGY & PHARMACY | ATAZANAVIR | SIMVASTATIN | drug-drug interaction | PROTEASE INHIBITORS | Fluorobenzenes - pharmacokinetics | Pyrroles - pharmacokinetics | Darunavir | Ethinyl Estradiol - pharmacokinetics | Humans | Pyrrolidinones - pharmacokinetics | Male | Fluorobenzenes - administration & dosage | Indoles - administration & dosage | Lopinavir - pharmacokinetics | Anti-HIV Agents - administration & dosage | Pyrrolidinones - administration & dosage | Tenofovir | Deoxycytidine - pharmacokinetics | Drug Interactions | Pyrroles - administration & dosage | Contraceptives, Oral - administration & dosage | Patient Safety | Atazanavir Sulfate | Contraceptives, Oral - pharmacokinetics | Phosphinic Acids - administration & dosage | Raltegravir Potassium | Emtricitabine | Adenine - analogs & derivatives | Pyridines - administration & dosage | Risk Assessment | Simvastatin - administration & dosage | Deoxycytidine - administration & dosage | Phosphinic Acids - pharmacokinetics | Rosuvastatin Calcium | Adenine - pharmacokinetics | Sulfonamides - pharmacokinetics | Cross-Over Studies | Cytochrome P-450 CYP3A - metabolism | Atorvastatin | Cytochrome P-450 CYP2D6 - metabolism | Least-Squares Analysis | Lopinavir - administration & dosage | Pyrimidines - pharmacokinetics | Oligopeptides - administration & dosage | Deoxycytidine - analogs & derivatives | Sulfonamides - administration & dosage | Cytochrome P-450 CYP2D6 Inhibitors | Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage | Heptanoic Acids - pharmacokinetics | Pyridines - pharmacokinetics | Reverse Transcriptase Inhibitors - administration & dosage | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacokinetics | Reverse Transcriptase Inhibitors - pharmacokinetics | Heptanoic Acids - administration & dosage | Female | Ethinyl Estradiol - administration & dosage | Androstenes - pharmacokinetics | Double-Blind Method | Ritonavir - administration & dosage | Pyrimidines - administration & dosage | Oligopeptides - pharmacokinetics | Linear Models | Simvastatin - pharmacokinetics | Androstenes - administration & dosage | Adenine - administration & dosage | Organophosphonates - pharmacokinetics | Organophosphonates - administration & dosage | Cytochrome P-450 CYP3A Inhibitors | Ritonavir - pharmacokinetics | Anti-HIV Agents - pharmacokinetics | Indoles - pharmacokinetics | Drug Combinations | Urine | Simvastatin | Drug interactions | Cytochrome P-450 | HIV (Viruses) | Complications and side effects | Analysis | Electrocardiogram | Electrocardiography | DNA polymerases | Ethinyl estradiol | Dosage and administration | Index Medicus | EKG | Antiviral agents | Urinalysis | Ritonavir | tenofovir | Cytochrome P450 | Lopinavir | ethinylestradiol | Blood | Infection | non-nucleoside reverse transcriptase inhibitors | Antiviral activity | Drug interaction | Probes | CYP2D6 protein
Journal Article
JAMA, ISSN 0098-7484, 05/2014, Volume 311, Issue 18, pp. 1870 - 1882
Journal Article
BMJ : British Medical Journal, ISSN 0959-8138, 5/2013, Volume 346, Issue 7911, pp. 14 - 14
Objective To examine the risk of new onset diabetes among patients treated with different HMG-CoA reductase inhibitors (statins).Design Population based cohort... 
RESEARCH | Secondary prevention | Depopulation | Population growth | Diabetes | Older adults | MEDICINE, GENERAL & INTERNAL | METAANALYSIS | THERAPY | EVENTS | CHOLESTEROL | CORONARY | DISEASE | PREVENTION | RANDOMIZED CONTROLLED-TRIAL | MELLITUS | ATORVASTATIN | Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage | Simvastatin - adverse effects | Cardiovascular Diseases - prevention & control | Humans | Male | Fluorobenzenes - administration & dosage | Heptanoic Acids - adverse effects | Diabetes Mellitus, Type 2 - epidemiology | Incidence | Dose-Response Relationship, Drug | Pyrroles - administration & dosage | Cardiovascular Diseases - epidemiology | Heptanoic Acids - administration & dosage | Pravastatin - adverse effects | Pyrroles - adverse effects | Diabetes Mellitus, Type 2 - etiology | Female | Retrospective Studies | Odds Ratio | Dyslipidemias - drug therapy | Pyrimidines - administration & dosage | Simvastatin - administration & dosage | Proportional Hazards Models | Rosuvastatin Calcium | Treatment Outcome | Atorvastatin Calcium | Dyslipidemias - epidemiology | Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects | Pravastatin - administration & dosage | Ontario - epidemiology | Pyrimidines - adverse effects | Sulfonamides - adverse effects | Aged | Fluorobenzenes - adverse effects | Diabetes Mellitus, Type 2 - chemically induced | Population Surveillance | Sulfonamides - administration & dosage | Cohort Studies | Inhibitor drugs | Risk assessment | Statins | Clinical outcomes | Index Medicus | Abridged Index Medicus
Journal Article
Journal Article
Drug Metabolism and Disposition, ISSN 0090-9556, 01/2010, Volume 38, Issue 1, pp. 168 - 176
This study investigated the role of a multispecific organic anion transporter, Oatp1a4/ Slco1a4 , in drug transport across the blood-brain barrier. In vitro... 
LOCALIZATION | INVOLVEMENT | POLYPEPTIDE-2 | PENETRATION | PHARMACOLOGY & PHARMACY | RAT-BRAIN | OATP2 | BCRP/ABCG2 | 17-BETA-ESTRADIOL-D-17-BETA-GLUCURONIDE | CANCER RESISTANCE PROTEIN | P-GLYCOPROTEIN | Fluorobenzenes - pharmacokinetics | Gene Expression - genetics | Pyrimidines - blood | Humans | Ion Pumps - genetics | Fluorobenzenes - administration & dosage | Quinolines - administration & dosage | Pyrimidines - metabolism | Brain - metabolism | Quinolines - pharmacokinetics | Choroid Plexus - blood supply | ATP-Binding Cassette Transporters - genetics | Ochratoxins - administration & dosage | Cell Membrane - metabolism | Cerebral Cortex - drug effects | Capillaries - metabolism | Fluorobenzenes - metabolism | Tetrahydroisoquinolines - pharmacology | Organic Cation Transport Proteins - metabolism | Pravastatin - metabolism | Liver - metabolism | Rosuvastatin Calcium | Sulfonamides - pharmacokinetics | Blood-Brain Barrier - metabolism | Mice, Knockout | Brain - drug effects | Taurocholic Acid - administration & dosage | Pravastatin - administration & dosage | Enkephalin, D-Penicillamine (2,5)- - administration & dosage | Pyrimidines - pharmacokinetics | Mice | Kinetics | Organic Cation Transport Proteins - genetics | Pravastatin - pharmacokinetics | Sulfonamides - administration & dosage | Quinolines - blood | Digoxin - metabolism | Taurocholic Acid - metabolism | Choroid Plexus - metabolism | Taurocholic Acid - blood | Ochratoxins - pharmacokinetics | ATP-Binding Cassette, Sub-Family B, Member 1 - antagonists & inhibitors | Ochratoxins - metabolism | Cerebral Cortex - metabolism | Organic Anion Transporters - metabolism | Brain - blood supply | Sulfonamides - blood | Organic Anion Transporters - genetics | Transfection | Fluorobenzenes - blood | Enkephalin, D-Penicillamine (2,5)- - pharmacokinetics | Recombinant Proteins - metabolism | Cell Line | Pyrimidines - administration & dosage | Mice, Inbred C57BL | Recombinant Proteins - genetics | Blood-Brain Barrier - drug effects | Digoxin - pharmacokinetics | Quinolines - metabolism | Taurocholic Acid - pharmacokinetics | Liver - blood supply | Pharmaceutical Preparations - metabolism | Animals | Digoxin - administration & dosage | Enkephalin, D-Penicillamine (2,5)- - metabolism | Acridines - pharmacology | Sulfonamides - metabolism | Index Medicus
Journal Article
Lancet, The, ISSN 0140-6736, 2015, Volume 386, Issue 9992, pp. 452 - 460
Journal Article
Clinical Pharmacology & Therapeutics, ISSN 0009-9236, 12/2007, Volume 82, Issue 6, pp. 726 - 733
Thirty‐two healthy volunteers with different SLCO1B1 genotypes ingested a 20 mg dose of atorvastatin and 10 mg dose of rosuvastatin with a washout period of 1... 
COA REDUCTASE INHIBITOR | ANION TRANSPORTING POLYPEPTIDE | PLASMA-CONCENTRATIONS | PHARMACOLOGY & PHARMACY | HEPATIC-UPTAKE | TRANSPLANT RECIPIENTS | HEALTHY-VOLUNTEERS | INDUCED MYOPATHY | OATP-C SLC21A6 | SINGLE NUCLEOTIDE POLYMORPHISMS | CLINICAL-RELEVANCE | Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage | Fluorobenzenes - pharmacokinetics | Prospective Studies | Pyrroles - pharmacokinetics | Area Under Curve | Pyrimidines - blood | Heptanoic Acids - pharmacokinetics | Humans | Hydroxymethylglutaryl-CoA Reductase Inhibitors - blood | Male | Reference Values | Fluorobenzenes - administration & dosage | Organic Anion Transporters - metabolism | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacokinetics | Sulfonamides - blood | Organic Anion Transporters - genetics | Pyrroles - administration & dosage | Heptanoic Acids - administration & dosage | Adult | Female | Fluorobenzenes - blood | European Continental Ancestry Group - genetics | Administration, Oral | Pyrimidines - administration & dosage | Liver - metabolism | Rosuvastatin Calcium | Genotype | Pyrroles - blood | Sulfonamides - pharmacokinetics | Polymorphism, Genetic | Atorvastatin Calcium | Pyrimidines - pharmacokinetics | Solute Carrier Organic Anion Transporter Family Member 1b1 | Heptanoic Acids - blood | Sulfonamides - administration & dosage | Index Medicus | Abridged Index Medicus
Journal Article
Clinical Pharmacology & Therapeutics, ISSN 0009-9236, 05/2004, Volume 75, Issue 5, pp. 455 - 463
Journal Article
The American Journal of Cardiology, ISSN 0002-9149, 2003, Volume 92, Issue 2, pp. 152 - 160
Journal Article
Lancet, The, ISSN 0140-6736, 2010, Volume 376, Issue 9738, pp. 333 - 339
Summary Background HDL-cholesterol concentrations are inversely associated with occurrence of cardiovascular events. We addressed, using the JUPITER trial... 
Internal Medicine | MEDICINE, GENERAL & INTERNAL | ATHEROSCLEROSIS | PREVENTION | RANDOMIZED-TRIAL | TORCETRAPIB | TRIGLYCERIDES | PRAVASTATIN | HYPERCHOLESTEROLEMIA | CORONARY-HEART-DISEASE | A-I | HIGH-DENSITY-LIPOPROTEIN | Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage | Myocardial Infarction - blood | Humans | Middle Aged | Male | Fluorobenzenes - administration & dosage | Angioplasty - statistics & numerical data | Incidence | C-Reactive Protein - metabolism | Adult | Cholesterol, LDL - blood | Female | Stroke - prevention & control | Double-Blind Method | Drug Administration Schedule | Pyrimidines - administration & dosage | Risk Factors | Rosuvastatin Calcium | Cholesterol, LDL - drug effects | Treatment Outcome | Biomarkers - blood | Stroke - blood | Sulfonamides - therapeutic use | Pyrimidines - therapeutic use | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Primary Prevention - methods | Angina, Unstable - prevention & control | Cholesterol, HDL - blood | Aged | Myocardial Infarction - prevention & control | Fluorobenzenes - therapeutic use | Sulfonamides - administration & dosage | Angina, Unstable - etiology | Complications and side effects | Hypercholesterolemia | Dosage and administration | Research | Cardiovascular diseases | Drug therapy | Risk factors | Statins | Fees & charges | Studies | Women | Heart attacks | Data collection | Cardiovascular disease | Apolipoproteins | Cholesterol | Index Medicus | Abridged Index Medicus
Journal Article
Clinical Pharmacology & Therapeutics, ISSN 0009-9236, 08/2009, Volume 86, Issue 2, pp. 197 - 203
The ABCG2 c.421C>A single‐nucleotide polymorphism (SNP) was determined in 660 healthy Finnish volunteers, of whom 32 participated in a pharmacokinetic... 
BCRP GENE POLYMORPHISMS | ACID | HUMAN PLASMA | SLCO1B1 POLYMORPHISM | LACTONE FORMS | TRANSPORTER ABCG2 | PHARMACOLOGY & PHARMACY | INDUCED MYOPATHY | CANCER RESISTANCE PROTEIN | SINGLE NUCLEOTIDE POLYMORPHISMS | P-GLYCOPROTEIN | ATP Binding Cassette Transporter, Sub-Family G, Member 2 | Fluorobenzenes - pharmacokinetics | Pyrroles - pharmacokinetics | Pyrroles - urine | Area Under Curve | Drug Resistance, Multiple | Pyrimidines - blood | Heptanoic Acids - pharmacokinetics | Humans | Male | Reference Values | Fluorobenzenes - administration & dosage | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacokinetics | Sulfonamides - blood | ATP-Binding Cassette Transporters - genetics | Sulfonamides - urine | Pyrroles - administration & dosage | Fluorobenzenes - urine | Heptanoic Acids - administration & dosage | Adult | Female | Fluorobenzenes - blood | Neoplasm Proteins - genetics | European Continental Ancestry Group - genetics | Pyrimidines - administration & dosage | Rosuvastatin Calcium | Genotype | Linear Models | Pyrroles - blood | Sulfonamides - pharmacokinetics | Cross-Over Studies | Atorvastatin Calcium | Anticholesteremic Agents - pharmacokinetics | Heptanoic Acids - urine | Finland | Pyrimidines - pharmacokinetics | Polymorphism, Single Nucleotide | Pyrimidines - urine | Heptanoic Acids - blood | Sulfonamides - administration & dosage | Index Medicus | Abridged Index Medicus
Journal Article